TWO MAJOR ONES: Adriamycin (doxorubicin) and Cytoxan is a great combination regimen used in breast cancer. The major long term side effects for both of these drugs is secondary leukemias, risk is around 1%. For adriamycin (doxorubicin) there is a concern for cardiotoxicity, but risk rises with cumulative dose. Risk is less than 10%. Patients get an echocardiogram or muga scan prior to therapy to evaluate heart status. Talk to your md.
Answered 8/19/2019
5.9k views
Both drugs have...: Significant ses. Anthracyclines like adriamycin (doxorubicin) are associated with cardiotoxicity. A cardioprotectant known as zinecard is being evaluated in many settings to try to mitigate this. Being topoisomerase inhibitors, anthracyclines carry a risk of secondary leukemia. Cytoxan also has this risk, but it tends to develop later. Hemorrhagic cystitis and SIADH are also Cytoxan ses. There are others tho.
Answered 9/17/2018
4.9k views
3 doctors weighed in across 2 answers
3 doctors weighed in across 2 answers
A doctor has provided 1 answer
A doctor has provided 1 answer
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question